Obiettivo Esophageal carcinoma (EC) is among the top 10 deadliest cancers worldwide. The current standardtherapy for ES is neoadjuvant (pre-operative) chemoradiation (NACR) followed by surgery. However,only 30% of patients achieve a complete pathological response (CPR) and long-term survival.Understanding the mechanisms of response to NACR is hence pivotal to better stratify patients andinform the design of more efficacious therapies. Evidence from some tumors suggests that NACR is“immunogenic” and stimulates anti-cancer immune responses, which may contribute to the longtermeffects of successful treatments. Tumor neo-antigens, generated by somatically mutatedcancer genes, have been recently implicated in the activation of the most efficient anti-tumor T cellresponse capable of controlling tumor progression, induced by immune checkpoint blockadeimmunotherapy. This raises the question as to whether clinical responses induced by NACR in afraction of ECs may be linked to the stimulation of clinically relevant T cell responses against tumorneoantigens, implying that activating tumor immunity in the non-responding ones may improveclinical responses. Objective of this proof-of-concept study is hence to address this question throughthe implementation of a high-throughput platform to assess neoantigen-specific T cell responses inECs in the course of NACR. Campo scientifico medical and health sciencesclinical medicinesurgerymedical and health sciencesclinical medicineoncologymedical and health sciencesbasic medicineimmunologyimmunotherapy Programma(i) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Argomento(i) MSCA-IF-2016 - Individual Fellowships Invito a presentare proposte H2020-MSCA-IF-2016 Vedi altri progetti per questo bando Meccanismo di finanziamento MSCA-IF-EF-SE - Society and Enterprise panel Coordinatore OSPEDALE SAN RAFFAELE SRL Contribution nette de l'UE € 168 277,20 Indirizzo VIA OLGETTINA 60 20132 Milano Italia Mostra sulla mappa Regione Nord-Ovest Lombardia Milano Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 168 277,20
